English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Autoimmune skin disease patients are standardly screened for tuberculosis (TB) via interferon-gamma release assays (IGRAs) prior to starting immunosuppressive drugs or enrolling in clinical trials. Two commercial IGRAs, T-SPOT.TB (T-SPOT) and QuantiFERONTb Gold (QFT-G), are reported as either determinate (positive or negative) or indeterminate. Both tests utilize similar immunoenzymatic reactions for interferongamma detection, but differ in quantification. Though QFT-G is more widely used, studies have demonstrated that T-SPOT has lower rates of indeterminate results in immunosuppressed patients. The newest generation of QFT-G, QuantiFERON-TB Gold Plus (QFT-Plus), has not been compared to T-SPOT in this patient population. We aim to investigate the performance of T-SPOT and QFT-Plus in autoimmune skin disease patients. This prospective study included 48 patients. Venous blood samples were collected and underwent TB screening with QFT-Plus and T-SPOT IGRAs. The proportions of indeterminate and determinate results among the two tests were compared. There were 2 indeterminate results with QFT-Plus and no indeterminate results with T-SPOT. There was one positive result for QFT-Plus and T-SPOT. Using a one-tailed Fischer test, there was no statistical significance when comparing QFT-Plus and T-SPOT in autoimmune skin disease patients (P=0.25). Although not statistically significant, it is clinically important as indeterminate results preclude these patients from receiving necessary treatment. Compared to previous studies on QFT-G, QFT-Plus showed improvement in reducing the amount of indeterminate results. We suggest using T-SPOT in TB screening for autoimmune skin disease patients who have an indeterminate QFT-G or QFT-Plus, as this test did not display any indeterminate results.

AB021. Comparing the performance of two interferon-gamma release assays in autoimmune skin disease patients: a prospective study